Nanobiotix is trading at $33.14, up 5.12% in pre-market after updated Phase 1 melanoma results presented at ESMO. - Among 24 heavily pretreated patients: 41.7% response rate, including four complete responses; median overall survival was 17.8 months. - Nanobiotix announced data on October 24; coverage linked prior-session gains to results. Price history shows gains in several recent sessions, including October 26. - Small, uncontrolled study; larger randomized trials are needed to confirm findings. Search results found no separate overnight announcement.